376 related articles for article (PubMed ID: 9580485)
1. [Clinical experience with an alpha glucosidase inhibitor (acarbose) in the treatment of non-insulin-dependent diabetes. Multicenter study].
García de los Ríos M; Mujica V; Muñoz S; Durruty P; Larenas G; López MI; Kuzmanic A; Pérez J; Flaskamp R; Cumsille F
Rev Med Chil; 1997 Aug; 125(8):856-62. PubMed ID: 9580485
[TBL] [Abstract][Full Text] [Related]
2. Effects of alpha-glucosidase inhibitor (acarbose) combined with sulfonylurea or sulfonylurea and metformin in treatment of non-insulin-dependent diabetes mellitus.
Vannasaeng S; Ploybutr S; Nitiyanant W; Peerapatdit T; Vichayanrat A
J Med Assoc Thai; 1995 Nov; 78(11):578-85. PubMed ID: 8576667
[TBL] [Abstract][Full Text] [Related]
3. [Non-insulin-dependent diabetes mellitus associated with nonalcoholic liver cirrhosis: an evaluation of treatment with the intestinal alpha-glucosidase inhibitor acarbose].
Gentile S; Turco S; Guarino G; Oliviero B; Rustici A; Torella R
Ann Ital Med Int; 1999; 14(1):7-14. PubMed ID: 10528419
[TBL] [Abstract][Full Text] [Related]
4. [Effect of acarbose on postprandial increase in blood glucose. Additive acute effect of once daily administration in insulin treated diabetes].
Ledermann H; Höxter G
Fortschr Med; 1994 Nov; 112(32):467-70. PubMed ID: 7821886
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of acarbose as monotherapy in NIDDM patients.
Deerochanawong C; Serirat S; Kornthong P
J Med Assoc Thai; 1996 Feb; 79(2):69-75. PubMed ID: 8868016
[TBL] [Abstract][Full Text] [Related]
6. Blood glucose concentrations and glycosuria during and after one year of acarbose therapy.
Aubell R; Boehme K; Berchtold P
Arzneimittelforschung; 1983; 33(9):1314-8. PubMed ID: 6357206
[TBL] [Abstract][Full Text] [Related]
7. Prolonged and enhanced secretion of glucagon-like peptide 1 (7-36 amide) after oral sucrose due to alpha-glucosidase inhibition (acarbose) in Type 2 diabetic patients.
Seifarth C; Bergmann J; Holst JJ; Ritzel R; Schmiegel W; Nauck MA
Diabet Med; 1998 Jun; 15(6):485-91. PubMed ID: 9632123
[TBL] [Abstract][Full Text] [Related]
8. [Evaluation of acarbose efficacy and safety for treatment of diabetes mellitus. Testing of observations under general health care conditions].
Sieradzki J; Soszyński P
Przegl Lek; 1999; 56(5):335-41. PubMed ID: 10554569
[TBL] [Abstract][Full Text] [Related]
9. Long-term effect of alpha-glucosidase inhibitor on late dumping syndrome.
Hasegawa T; Yoneda M; Nakamura K; Ohnishi K; Harada H; Kyouda T; Yoshida Y; Makino I
J Gastroenterol Hepatol; 1998 Dec; 13(12):1201-6. PubMed ID: 9918426
[TBL] [Abstract][Full Text] [Related]
10. Effects of prolonged (6 months) alpha-glucosidase inhibition on blood glucose control and insulin requirements in patients with insulin-dependent diabetes mellitus.
Dimitriadis G; Karaiskos C; Raptis S
Horm Metab Res; 1986 Apr; 18(4):253-5. PubMed ID: 3519413
[TBL] [Abstract][Full Text] [Related]
11. Acarbose, an alpha-glucosidase inhibitor for non-insulin-dependent diabetes.
Welborn TA
Med J Aust; 1998 Jan; 168(2):76-8. PubMed ID: 9469188
[No Abstract] [Full Text] [Related]
12. Effects of acarbose, an alpha-glucosidase inhibitor (Bay G 5421), on orally loaded glucose, maltose and sucrose and on blood glucose control in non-insulin-dependent diabetics.
Hayakawa T; Noda A; Kondo T; Okumura N
Nagoya J Med Sci; 1985 Jan; 47(1-2):35-41. PubMed ID: 3887176
[No Abstract] [Full Text] [Related]
13. [Effectiveness and tolerance of long-term acarbose therapy in diabetic patients with threatened secondary failure of sulfonylurea drug treatment].
Domke A; Willms B
Med Klin (Munich); 1994 Apr; 89(4):187-92. PubMed ID: 8015532
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of postprandial hyperglycemia by acarbose is a promising therapeutic strategy for the treatment of patients with the metabolic syndrome.
Yamagishi S; Nakamura K; Takeuchi M
Med Hypotheses; 2005; 65(1):152-4. PubMed ID: 15893133
[TBL] [Abstract][Full Text] [Related]
15. Effects of the alpha-glucosidase inhibitor acarbose on postprandial serum glucose and insulin concentrations in healthy dogs.
Robertson J; Nelson R; Kass P; Neal L
Am J Vet Res; 1999 May; 60(5):541-5. PubMed ID: 10328421
[TBL] [Abstract][Full Text] [Related]
16. Clinical efficacy of acarbose in diabetes mellitus: a critical review of controlled trials.
Scheen AJ
Diabetes Metab; 1998 Sep; 24(4):311-20. PubMed ID: 9805641
[TBL] [Abstract][Full Text] [Related]
17. Effect of acarbose in treatment of type II diabetes mellitus: a double-blind, crossover, placebo-controlled trial.
Soonthornpun S; Rattarasarn C; Thamprasit A; Leetanaporn K
J Med Assoc Thai; 1998 Mar; 81(3):195-200. PubMed ID: 9623011
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological regulation of blood glucose levels in non-insulin-dependent diabetes mellitus.
Bressler R; Johnson DG
Arch Intern Med; 1997 Apr; 157(8):836-48. PubMed ID: 9129543
[TBL] [Abstract][Full Text] [Related]
19. Clinical experience with acarbose as first line therapy in NIDDM.
Fölsch UR
Clin Invest Med; 1995 Aug; 18(4):312-7. PubMed ID: 8549018
[TBL] [Abstract][Full Text] [Related]
20. The mechanism of alpha-glucosidase inhibition in the management of diabetes.
Bischoff H
Clin Invest Med; 1995 Aug; 18(4):303-11. PubMed ID: 8549017
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
